|
|
|
May 2008
|
|
|
|
|
INTRODUCTION
MANAGERIAL
CLINICAL
 |
Managed Care and Cancer Outcomes for Medicare Beneficiaries With Disabilities |
 |
|
Richard G. Roetzheim, MD, MSPH; Thomas N. Chirikos, PhD; Kristen J. Wells, PhD, MPH; Ellen P. McCarthy, PhD, MPH; Long H. Ngo, PhD; Donglin Li, MD, MPH; Reed E. Drews, MD; and Lisa I. Iezzoni, MD, MSc
This study showed better outcomes for disabled Medicare patients with breast cancer but not those with lung cancer when they were enrolled in HMOs.
Abstract :
Full Text :
Appendix : PDF
|
POLICY
 |
Second-line and Third-line Chemotherapy for Lung Cancer: Use and Cost |
 |
|
Scott D. Ramsey, MD, PhD; Renato G. Martins, MD; David K. Blough, PhD; Lauri S. Tock, MHA; Deborah Lubeck, PhD; and Carolina M. Reyes, PhD
Using health insurance claims, we identified common first-, second-, and third-line chemotherapy regimens for patients with lung cancer and associated utilization and costs of care.
Abstract :
Full Text :
PDF
|
MANAGERIAL
 |
No Time to Waste: Decreasing Patient Wait Times for Chemotherapy Administration Using Automated Prioritization in an Oncology Pharmacy System |
 |
|
Hanan J. Aboumatar, MD, MPH; Laura E. Winner, MBA, RN; Richard O. Davis, PhD; Peter B. Trovitch, PharmD; Maureen M. Berg, RN, OCN; Katherina M. Violette, BSN, RN; Wells A. Messersmith, MD; Karen K. Maylor, RN; and Christoph U. Lehmann, MD
Using a prioritization algorithm in an oncology pharmacy system at the Johns Hopkins University, patient wait times for chemotherapy administration were significantly decreased.
Abstract :
Full Text :
PDF
|
CLINICAL
 |
The Cost of Treating Skeletal-Related Events in Patients With Prostate Cancer |
 |
|
Maureen J. Lage, PhD; Beth L. Barber, PhD; David J. Harrison, PhD; and Sun Jun, MD, PhD
The analysis examines the annual economic effect of medically treating patients with prostate cancer and subsequent bone metastases.
Abstract :
Full Text :
PDF
|
 |
Complementary and Alternative Medicine Provider Use and Expenditures by Cancer Treatment Phase |
 |
|
William E. Lafferty, MD; Patrick T. Tyree, AA; Sean M. Devlin, MA; M. Robyn Andersen, PhD, MPH; and Paula K. Diehr, PhD
More than 26% of cancer patients see CAM providers, primarily for musculoskeletal problems; use does not vary by treatment phase, and associated expenditures are low.
Abstract :
Full Text :
PDF : Appendix
|
LIST OF PEER REVIEWERS
LETTERS TO THE EDITORS
|
|
|
|
|
|
|
|